Safety and Efficacy of Recombinant Factor IX Fusion Protein (Rix-Fp) in Previously Untreated Patients with Haemophilia B

R Lemons, M Wang,J Curtin, M L Lepatan,C Male,F Peyvandi,M Prondzinski Von Depka, R Wang,W McKeand,W Seifert, J Oldenburg

GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark Hämostaseologie（2023）

引用 0|浏览4

暂无评分

摘要

Introduction Recombinant fusion protein linking coagulation factor IX (FIX) with albumin (rIX-FP) has been shown to be an effective and well-tolerated treatment for paediatric and adult patients with severe haemophilia B who had been previously treated with factor replacement therapy. This study investigated the safety and efficacy of rIX-FP in previously untreated patients (PUPs) ([Fig. 1]).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要